Posted on March 20th 2022
A coordinated effort between The Pulmonary Vascular Research Institute (PVRI) and industry partners aims to ensure pulmonary arterial hypertension patients affected by the war in Ukraine receive supplies of life-sustaining drugs.
Industry partners have responded to calls of support from the PVRI and will donate sufficient quantities of drugs to cover the needs of patients via support from the Cardiac Society of Poland. All parties are now working towards the delivery of these effective therapies to those living in Ukraine or crossing the border into Poland as refugees.
The PVRI’s established collaborative industry partnership has co-ordinated this effort through its Access to Care and patient engagement initiatives, in collaboration with Dr Ewa Mroczec and Dr Adam Torbicki in Poland, and Dr Yuriy Sirenko (pictured below, centre) in Ukraine.
The organisation will continue to utilise its network of key stakeholders to provide support, where possible, to all patients affected by the supply disruption.
Professor Paul Corris, Chairman of the Board at the PVRI, said:
“The PVRI is proud to have used its global influence and collaborative approach with industry to facilitate the delivery of drugs to those affected by the conflict in Ukraine. We are expecting to have similar success working alongside other pharmaceutical companies in providing the full range of therapies available, and to all patients affected by this terrible war.”
The PVRI was established in 2006 as a way for fellow scientists, clinicians and academics to come together and share knowledge on pulmonary vascular disease.
At the PHA UK, we have set up this online message board for people to share their words of hope, support, poetry or prayer for those affected by the conflict in Ukraine. You can watch our Chair, Dr Iain Armstrong, explain more here.
